While previous studies have reported amelioration, attenuation, and modulation of DSS-induced colon structural damage and inflammation by pharmacologically or genetically inhibiting the NPY system systemically [30, 31, 39], our findings suggest that Y2 receptor inhibition does not alter any of the traditionally evaluated aspects of DSS-induced colitis and Y1 inhibition failed to protect against colon structural damage. The gene discussed is NPY; the disease is colitis.